Trovagene (TROV) Tops Q3 EPS by 4c

Trovagene (NASDAQ: TROV) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $57 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Trovagene (TROV) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Tenon Medical (TNON) Misses Q2 EPS by 395c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18